Promising new combos in cancer research pipelines

Four more combination trials of interest in cancer research that may be worth watching out for

November 2, 2016

ESMO16 Gems from the Poster Halls Part 2

Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...

November 1, 2016

Insights from biomarkers in ovarian cancer

Can biomarkers help us improve clinical trial outcomes?

October 25, 2016

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016

New Directions in Advanced Lung Cancer

Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…

October 19, 2016

ESMO16 Day 3 Daily Digest

Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium

October 10, 2016

ESMO16 Day 2 Digest

Commentary on Day 2 at ESMO16

October 8, 2016

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016

ESMO16 Congress Day 1 Digest

Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.

October 7, 2016

ESMO16 Preview 7 Key Trials in Breast Cancer

A look at some of the key breast cancer abstracts to watch out for at #ESMO16 in Copenhagen

September 14, 2016

ESMO16 Preview Novel Targeted Therapies

Five key approaches in developmental therapeutics in the spotlight at ESMO16

September 13, 2016

What’s Hot in Ovarian Cancer at ESMO16?

A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect

September 8, 2016

ESMO16 What’s Hot in Head and Neck Cancer?

What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?

September 7, 2016

ESMO16 Preview on Late Breaking Abstracts in Lung Cancer

A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?

September 6, 2016

ESMO16 Preview 1 Novel Target Data Offers Potential to Overcome Barriers to Cancer Drug Resistance

Overcoming barriers to resistance in epithelial cancers - a look at a novel oncogenic target

September 1, 2016